Canada markets closed

RepliCel Life Sciences Inc. (RP.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.09000.0000 (0.00%)
At close: 03:13PM EST
Full screen
Previous Close0.0900
Open0.0950
Bid0.0900 x 0
Ask0.1000 x 0
Day's Range0.0800 - 0.0950
52 Week Range0.0800 - 0.3000
Volume725
Avg. Volume6,774
Market Cap3.468M
Beta (5Y Monthly)0.97
PE Ratio (TTM)N/A
EPS (TTM)-0.0590
Earnings DateNov 27, 2015 - Nov 30, 2015
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    RepliCel Announces Material Patent Milestones in Key Markets

    RepliCel Life Sciences Inc. (OTCPK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing novel, next-generation injection technologies as well as cell-based regenerative medicine products in aesthetics and orthopedics, is pleased to announce the granting of several patents covering novel aspects of the DermaPrecise™ product portfolio, as well as the granting and/or allowance of four other patent applications for its skin rejuvenation

  • ACCESSWIRE

    DermaPrecise(TM) Injection System Shown to Produce Consistently High Cell Count and Viability for Cell Therapy Injections

    RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announced today it has received test results showing that cells injected through the DermaPrecise™ Injector maintained >99% viability.

  • ACCESSWIRE

    RepliCel’s Manufacturing Inspected by Japan’s PMDA

    RepliCel Life Sciences Inc. (OTCPINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing novel, next-generation injection technologies as well as regenerative medicine products in aesthetics and orthopedics, is pleased to announce the completion, last week, of an inspection of RepliCel's NBDS cell therapy manufacturing at its Austrian contract manufacturing facility owned and operated by Innovacell KK (Tokyo, Japan).